Wanhuida Intellectual Property

Wu Xiaoping of Wanhuida Intellectual Property analyses a decision that carries great weight in differentiating between monopolistic behaviour and the exercise of valid intellectual property rights

Honghui Hu of Wanhuida Intellectual Property explains that a CNIPA ruling on a patent covering an antidepressant could help to determine the patentability of pharmaceutical compounds

Wu Xiaohui of Wanhuida Intellectual Property explains a pioneering case heard by the Intellectual Property Court of the Supreme People’s Court and considers its implications for original and generic drug makers

Jianhui Li of Wanhuida Intellectual Property explains how China addresses the question of whether the features of an administration process limit a patented product and distinguish it from prior art

Yue Guan of Wanhuida Intellectual Property reports on a case in China that has implications for the drafting of compound patents incorporating Markush claims

Feng Zheng and Xiaoyang Yang of Wanhuida outline the various defence mechanisms patentees have at their disposal when facing infringement accusations in China